Clinical Trial Update: Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the immunogenicity and safety of Sanofi Pasteur's AVAXIM 80U hepatitis A vaccine in pediatric participants, given with a booster dose. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A

Drugs mentioned

• AVAXIM 80U Pediatric Hepatitis A Vaccine (hepatitis A vaccine, inactivated)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Hepatitis A | Phase 3 | Status: COMPLETED